Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | TARBP2 | Q15633 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652306 | 0.89 | KDM4E (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL370013 | 0.85 | MAPT (0.46) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL4100807 | 0.85 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1GAAALOX15MEN1 | |
| Hydrochloric Acid SCHEMBL4100850 | 0.84 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1GAAALOX15MEN1 | |
| SCHEMBL21858188 | 0.83 | SMN1; SMN2 (0.45) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL369164 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL21858180 | 0.82 | MAPT (0.43) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL25191628 | 0.81 | MAPT (0.47) | ALDH1A1KDM4EHSD17B10MAPK1HPGD | |
| SCHEMBL3580396 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 | |
| SCHEMBL1645500 | 0.81 | DCTPP1 (0.47) | SMN1; SMN2ALDH1A1KDM4EHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671878-B | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022135534-A1 | SUBSTITUTED NITROGEN-CONTAINING BICYCLIC COMPOUND AND USE THEREOF | 广东东阳光药业有限公司 | 2022-06-30 | — | — | WO | disclosed |
| CN-114671878-A | Substituted nitrogen-containing bicyclic compounds and uses thereof | 广东东阳光药业有限公司 | 2022-06-28 | — | — | CN | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
| EP-1836188-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| US-20070105900-A1 | Pharmaceutical compounds | ATEX THERAPEUTICS, LIMITED (GB) | 2007-05-10 | — | — | US | disclosed |
| WO-2006070198-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| EP-1648449-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005002576-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | SMN1; SMN2 3277/4885ALDH1A1 3914/4885KDM4E 990/4885 |
| US-20070105900-A1 | Pharmaceutical compounds | AURKA, AURKC, CDK1 | SMN1; SMN2 4245/4885ALDH1A1 1875/4885KDM4E 1274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.